ABBV-383 for Waldenström macroglobulinemia that came back
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called ABBV-383 for people with Waldenström macroglobulinemia that has returned or stopped responding to treatment. The drug is given as an infusion and aims to attack the cancer cells. This might help if you've already tried a BTK inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to have tried a Bruton's tyrosine kinase (BTK) inhibitor before, unless it's not safe for you due to other medical reasons. BTK inhibitors are a type of targeted therapy for blood cancers.
- Your blood test must show a certain level of a protein called IgM (at least 500 mg/dL).
- You should be able to take care of yourself and be up and about (with at least some help if needed).
- You should not have had this drug (ABBV-383) or similar antibody treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This study tests a new approach for people with Waldenström macroglobulinemia who have already been on ibrutinib and are doing well but not completely better. It adds two more medicines (bendamustine and rituximab) to see if this combination can achieve a deeper response and allow you to stop treatment after a set period.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
Hear when a new Recurrent Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.